QuidelOrtho (QDEL) CFO nets stock from RSU vesting and tax withholding

Rhea-AI Filing Summary

QuidelOrtho Corporation’s Chief Financial Officer Joseph M. Busky reported routine equity compensation activity. On January 29, 2026, 8,425 restricted stock units vested, converting into the same number of shares of common stock at $0 per share. To cover related tax withholding, 2,602 shares were withheld at $27.41 per share rather than sold in the open market.

After these transactions, Busky directly holds 37,250 shares of QuidelOrtho common stock and 16,851 restricted stock units. An additional 6,920 shares are held indirectly by a trust. The remaining RSUs are scheduled to vest in equal portions in 2027 and 2028.

Insider Trade Summary

8,425 shares exercised/converted

Mixed 4 txns

Insider Busky Joseph M.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	8,425	$0.00	--
Grant/Award	Common Stock	8,425	$0.00	--
Tax Withholding	Common Stock	2,602	$27.41	$71K
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 16,851 shares (Direct); Common Stock — 39,852 shares (Direct); Common Stock — 6,920 shares (Indirect, By Trust)

Footnotes (1)

1. Reflects release of restricted stock units that were previously reported on a Form 4. Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. 8,425 shares vested on January 29, 2026; 8,425 shares will vest on January 29, 2027; and the remaining 8,426 shares will vest on January 29, 2028.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Busky Joseph M.

(Last) (First) (Middle)

9975 SUMMERS RIDGE ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/29/2026		A		8,425(1)	A	$0	39,852	D
Common Stock	01/29/2026		F		2,602(2)	D	$27.41	37,250	D
Common Stock								6,920	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	01/29/2026		M			8,425	(4)	(4)	Common Stock	8,425	$0	16,851	D

Explanation of Responses:

1. Reflects release of restricted stock units that were previously reported on a Form 4.

2. Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.

3. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

4. 8,425 shares vested on January 29, 2026; 8,425 shares will vest on January 29, 2027; and the remaining 8,426 shares will vest on January 29, 2028.

Remarks:

	/s/ Phillip S. Askim, attorney-in-fact for Joseph M. Busky	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did QuidelOrtho (QDEL) disclose for its CFO?

QuidelOrtho (QDEL) disclosed that CFO Joseph M. Busky had 8,425 restricted stock units vest into common shares. In connection with this vesting, shares were withheld to satisfy tax obligations, a standard mechanism for handling employment-related equity compensation.

How many QuidelOrtho (QDEL) shares vested for the CFO on January 29, 2026?

On January 29, 2026, 8,425 restricted stock units for QuidelOrtho’s CFO vested into 8,425 common shares. Each unit represents one common share, reflecting previously granted equity compensation now becoming owned stock in the company.

Why were 2,602 QuidelOrtho (QDEL) shares disposed of in this Form 4?

The 2,602 QuidelOrtho shares were withheld to cover tax withholding obligations tied to the RSU vesting. The filing shows these shares at a price of $27.41, indicating a non‑open‑market, tax-related disposition rather than a discretionary sale of shares.

How many QuidelOrtho (QDEL) shares does the CFO own after these transactions?

After the reported transactions, the CFO directly owns 37,250 QuidelOrtho common shares. He also has 6,920 shares held indirectly through a trust, along with 16,851 remaining restricted stock units that may convert into additional common shares as they vest.

What is the remaining vesting schedule for the CFO’s QuidelOrtho (QDEL) RSUs?

The remaining RSUs vest in three annual installments: 8,425 shares vested on January 29, 2026; another 8,425 will vest on January 29, 2027; and 8,426 will vest on January 29, 2028, assuming continued satisfaction of the award’s vesting conditions.

Are the QuidelOrtho (QDEL) CFO’s RSUs and shares held directly or via a trust?

Most of the CFO’s position is held directly, including 37,250 common shares and 16,851 restricted stock units. Separately, 6,920 common shares are reported as held indirectly by a trust, indicating an additional beneficial interest through that entity.